Cladribine Tablets Reduce Brain Atrophy in MS Patients, Merck Study Finds
EMD SorenoĀ has recently published Phase 3 clinical data showing that CladribineĀ tablets reduced the annualized rate of brain volume loss (BVL, brain atrophy) compared toĀ placebo in patients with relapsing-remitting multiple sclerosis (RRMS). The study, āReduced brain atrophy rates are associated with lower risk of disability progression…